Hematologic Neoplasms: Clinical Trials

13 trials for Hematologic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 terminated. 13 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 313Terminated 13
Phase 23Terminated 3

Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ATG Plus Low-dose PT-Cy for GVHD Prevention
Cyclophosphamid, ATG - Hematologic Malignancy
Phase 3TerminatedPeking University People's Hospital662023-11-012025-06-03
Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
Evusheld (tixagevimab+cilgavimab) IM or IV - SARS-CoV-2 Infection
Phase 3TerminatedMediMergent, LLC5502022-06-032023-09-08
Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases
Supportive Palliative Care, Clinical Management, Best Practice - Hematopoietic and Lymphoid Cell Neoplasm, Non-Neoplastic Hematologic and Lymphocytic Disorder
Phase 2 / Phase 3TerminatedFred Hutchinson Cancer Center4582019-08-152026-01-12
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Phase 3TerminatedKiadis Pharma632017-11-292022-05-24
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Phase 3TerminatedCTI BioPharma3112014-02-012021-11-18
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Phase 3TerminatedCTI BioPharma3272013-01-012020-09-29
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
SAR302503, Placebo - Hematopoietic Neoplasm
Phase 3TerminatedBristol-Myers Squibb2892011-12-312026-08-11
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Donor lymphocyte preparation depleted of host functional alloreactive T-cells - Myeloid Leukemia, Lymphoblastic Leukemia
Phase 2 / Phase 3TerminatedKiadis Pharma402009-08-012021-06-14
Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)
Hydroxyurea, Phlebotomy - Polycythemia Vera
Phase 3TerminatedConsorzio Mario Negri Sud3652008-05-012012-07-20
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Imatinib, Nilotinib (AMN107) - Myelogenous Leukemia
Phase 3TerminatedNovartis Pharmaceuticals62007-10-012011-11-07
Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients
heparin, concentrated citrate - Hematological Malignancies, Bacteremia
Phase 3TerminatedMaastricht University Medical Center2122006-07-012013-03-29
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
zoledronic acid, dexamethasone, thalidomide - Multiple Myeloma
Phase 3TerminatedH. Lee Moffitt Cancer Center and Research Institute902003-06-012014-04-17
Stem Cell Transplantation for Hematological Malignancies
Stem Cell Transplant, Busulfan, Cyclophosphamide - Leukemia, Lymphocytic, Acute, AML
Phase 2 / Phase 3TerminatedMasonic Cancer Center, University of Minnesota112000-06-072017-12-05

Narrower conditions

Bone Marrow Diseases (3)  ·  Myeloproliferative Disorders (3)  ·  Polycythemia Vera (3)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Anemia (2)  ·  Graft vs Host Disease (2)  ·  Hematologic Diseases (2)  ·  Leukemia, Myeloid (2)  ·  Multiple Myeloma (2)  ·  Myelodysplastic Syndromes (2)  ·  Primary Myelofibrosis (2)  ·  Splenomegaly (2)  ·  Thrombocythemia, Essential (2)  ·  Thrombocytopenia (2)

Broader conditions

Hemic and Lymphatic Diseases (13)  ·  Neoplasms (13)  ·  Neoplasms by Site (13)  ·  Hematologic Diseases (11)  ·  Neoplasms by Histologic Type (5)  ·  Cardiovascular Diseases (4)  ·  Immune System Diseases (4)  ·  Immunoproliferative Disorders (4)  ·  Lymphoproliferative Disorders (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Vascular Diseases (4)  ·  Bone Marrow Diseases (3)  ·  Bone Marrow Neoplasms (3)  ·  Hemorrhagic Disorders (3)

Interventions

Cyclophosphamide (3)  ·  11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (2)  ·  Stem Cell Transplantation (2)  ·  Antilymphocyte Serum (1)  ·  Bone Marrow Transplantation (1)  ·  Busulfan (1)  ·  Calcium Dobesilate (1)  ·  Dexamethasone (1)  ·  Doxorubicin (1)  ·  Filgrastim (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Heparin (1)  ·  Hydroxyurea (1)  ·  Imatinib Mesylate (1)  ·  Melphalan (1)

Sponsors

CTI BioPharma (2)  ·  Kiadis Pharma (2)  ·  Bristol-Myers Squibb (1)  ·  Consorzio Mario Negri Sud (1)  ·  Fred Hutchinson Cancer Center (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Maastricht University Medical Center (1)  ·  Masonic Cancer Center, University of Minnesota (1)  ·  MediMergent, LLC (1)  ·  Novartis Pharmaceuticals (1)  ·  Peking University People's Hospital (1)

Countries

United States (10)  ·  Belgium (6)  ·  Germany (6)  ·  Italy (6)  ·  Netherlands (5)  ·  United Kingdom (5)  ·  Australia (4)  ·  Canada (4)  ·  France (4)  ·  Czechia (3)  ·  Hungary (3)  ·  Russia (3)  ·  Spain (3)  ·  Brazil (2)  ·  Israel (2)

Top investigators

Andrea Velardi, MD (1)  ·  Beth Ziemba (1)  ·  Denis Claude Roy, Prof MD (1)  ·  Denis-Claude Roy, MD (1)  ·  Harry Schouten, MD (1)  ·  Katy Rezvani, MD PhD (1)  ·  Margaret MacMillan, MD (1)  ·  Melissa Alsina, MD (1)  ·  Mohamed Sorror, MD, MSc (1)  ·  Ralph Boccia, MD (1)  ·  Simran Singh (1)  ·  Stephan Mielke, MD (1)  ·  Stephan Mielke, Prof MD (1)

Results publications

PMID 33275766, PMID 23216616, PMID 24472814, PMID 26181658, PMID 34551507, PMID 39400386, PMID 40534493, PMID 42316774

NIH funding

2016 (1), R01CA227092 (1)